Abstract
Somdeb Jana, Richard Hoogenboom
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local citing links have been materialized yet.
The art of PEGylation: from simple polymer to sophisticated drug delivery system
10.3390/ijms26073102 · 2025
Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy
10.1016/j.jconrel.2014.12.008 · 2015
PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs
10.1016/j.xphs.2015.11.015 · 2016
Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies
10.2165/00003088-200342050-00002 · 2003
Pharmacokinetic and biodistribution properties of poly (ethylene glycol)–protein conjugates
10.1016/s0169-409x(03)00108-x · 2003
Protein PEGylation for cancer therapy: bench to bedside
10.1007/s12079-018-0492-0 · 2019
Chemistry of polyethylene glycol conjugates with biologically active molecules
10.1016/0169-409x(95)00023-z · 1995
Immunogenicity of polyethylene glycol based nanomedicines: mechanisms, clinical implications and systematic approach
2020
To PEGylate or not to PEGylate: immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives
10.1016/j.addr.2021.114079 · 2022
State of the art in PEGylation: the great versatility achieved after forty years of research
10.1016/j.jconrel.2011.10.037 · 2012
Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives
10.1002/anie.200902672 · 2010
PEGylated therapeutics in the clinic
10.1002/btm2.10600 · 2024
Maintaining safety with SARS-CoV-2 vaccines
10.1056/nejmra2035343 · 2021
Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals
10.1016/j.addr.2020.07.024 · 2020
Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats
10.1038/s41541-023-00766-z · 2023
Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients
10.1186/ar4500 · 2014
Anti-poly(ethylene glycol)(PEG) antibodies: from where are we coming and where are we going
10.3390/jnt5030007 · 2024
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions
10.1093/annonc/mdg374 · 2003
Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process
10.1016/j.molimm.2008.08.276 · 2008
Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement
10.1016/j.jconrel.2021.11.042 · 2022
Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors
1984
Anti-PEG antibodies in the clinic: current issues and beyond PEGylation
10.1016/j.jconrel.2016.06.040 · 2016
Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies
10.1021/acsnano.1c05922 · 2021
The curious case of anti-PEG antibodies
10.1039/d5nr02301g · 2025
Anti-PEG antibodies and their biological impact on PEGylated drugs: challenges and strategies for optimization
10.3390/pharmaceutics17081074 · 2025
Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines
10.1016/j.ijpharm.2023.123695 · 2024
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
10.1186/ar4497 · 2014
Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer
10.1016/j.jaci.2015.10.034 · 2016
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer
10.1016/j.jaci.2016.04.058 · 2016
Polyethylene glycol immunogenicity in nanomedicine
10.1038/s44222-025-00321-6 · 2025
PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective
10.1021/acs.bioconjchem.3c00174 · 2023
Anti-PEG antibodies in nanomedicine: mechanisms, risks, and opportunities
10.1016/j.addr.2026.115925 · 2026
A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse
10.1016/j.jconrel.2018.06.002 · 2018
Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection
10.1016/j.jconrel.2006.08.017 · 2006
Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein
10.1021/acs.molpharmaceut.5b00144 · 2015
PEG that reaction: a case series of allergy to polyethylene glycol
10.1002/jcph.1824 · 2021
Antibodies against poly(ethylene glycol) activate innate immune cells and induce hypersensitivity reactions to PEGylated nanomedicines
10.1021/acsnano.2c12193 · 2023
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: a report from the children’s oncology group
10.1002/pbc.26873 · 2018
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. Coli asparaginase in children with acute lymphocytic leukemia
10.3324/haematol.2020.258525 · 2022
Reporting of allergic reactions during Pfizer-BioNTech BNTT162B2 vaccination in Israel
10.1016/j.jaip.2022.07.012 · 2022
The future of poly(2-oxazoline)s
10.1016/j.eurpolymj.2022.111521 · doi-reference
Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles
10.1021/mp300159u · doi-reference
Poly(2-oxazoline) with pendant hydroxyl groups via a silyl ether-based protecting group
10.1021/acs.macromol.2c02050 · doi-reference
A non-antigenic randomized polyethylene glycol/poly(2-phenyl-2-oxazine)-based drug delivery platform
10.1002/marc.202500781 · doi-reference
Interactions of core cross-linked poly(2-oxazoline) and poly(2-oxazine) micelles with immune cells in human blood
10.1016/j.biomaterials.2021.120843 · doi-reference
Promotion of micelle stability via a cyclic hydrophilic moiety
10.1039/c8py00299a · doi-reference
Enhanced dispersion stability of gold nanoparticles by the physisorption of cyclic poly(ethylene glycol)
10.1038/s41467-020-19947-8 · doi-reference
The topology of poly(2-methyl-2-oxazine) shells on nanoparticles determines their interaction with serum and uptake by immune cells
10.1021/acs.biomac.4c01340 · doi-reference
Impact of drug conjugation site and corona chemistry on the therapeutic activity of polymer nanorod – drug conjugates
10.1002/adhm.202402029 · doi-reference
Drug specificity, synergy and antagonism in ultrahigh capacity poly(2-oxazoline)/poly(2-oxazine) based formulations
10.1021/jacs.7b05376 · doi-reference
Unexpected reactivity switch in the statistical copolymerization of 2-Oxazolines and 2-Oxazines enabling the one-step synthesis of amphiphilic gradient copolymers
10.1021/jacs.9b02607 · doi-reference
Length-tuneable biocompatible block copolymer nanorods with a poly(2-methyl-2-oxazine)-corona via heat-induced crystallisation-driven self-assembly
10.1039/d3py00399j · doi-reference
Self-assembly, drug encapsulation, and cellular uptake of block and gradient copolymers of 2-Methyl-2-oxazine and 2-n-propyl/butyl-2-oxazoline
10.1021/acs.macromol.1c01794 · doi-reference
Poly(cyclic imino ether)s beyond 2-Substituted-2-oxazolines
10.1002/marc.201100138 · doi-reference
Stealth nanorods via the aqueous living crystallisation-driven self-assembly of poly(2-oxazoline)s
10.1039/d1sc00938a · doi-reference
Antibody-mediated recognition of chiral poly(2-oxazoline) nanorods driven by enantioselectivity
10.1039/d6sc05017d · doi-reference
Influence of chirality on protein corona formation of low-fouling chiral poly(2-oxazoline) coated nanoparticles
10.1016/j.eurpolymj.2024.112964 · doi-reference
Probing the biocompatibility and immune cell Association of Chiral, water-soluble, bottlebrush poly(2-oxazoline)s
10.1021/acs.biomac.2c01105 · doi-reference
Synthesis and investigation of chiral poly(2,4-disubstituted-2-oxazoline)-based triblock copolymers, their self-assembly, and formulation with chiral and achiral drugs
10.1021/acs.macromol.2c00229 · doi-reference
Secondary structure formation of main-chain chiral poly(2-oxazoline)s in solution
10.1039/b921467d · doi-reference
A new route to optically active linear poly(propylenimine)
10.1021/ma60042a054 · doi-reference
Poly(sarcosine) and poly(2-ethyl-2-oxazoline) tethered to mRNA provide stealth properties to mRNA Polyplexes
10.1021/acsanm.5c00636 · doi-reference
POx-lipids as an alternative to PEG-lipids? Multimethod assessment of chemistry and structure
10.1021/acs.analchem.5c07351 · doi-reference
Poly(2-ethyl-2-oxazoline) (POx) as poly(ethylene glycol) (PEG)-lipid substitute for lipid nanoparticle formulations
10.1002/smll.202411354 · doi-reference
Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit
10.1002/mds.25625 · doi-reference
Poly(2-ethyl-2-oxazoline) conjugates with salicylic acid via degradable modular Ester linkages
10.1021/acs.biomac.0c00659 · doi-reference
Poly(2-ethyl-2-oxazoline)–doxorubicin conjugate-based dual endosomal pH-sensitive micelles with enhanced antitumor efficacy
10.1021/bc5004718 · doi-reference
Poly(2-ethyl-2-oxazoline) bottlebrushes: how nanomaterial dimensions can influence biological interactions
10.1016/j.eurpolymj.2021.110447 · doi-reference
Tuning drug release from polyoxazoline-drug conjugates
10.1016/j.eurpolymj.2019.109241 · doi-reference
Feasibility of poly(ethylene glycol) derivatives as diagnostic drug carriers for tumor imaging
10.1016/j.jconrel.2016.02.017 · doi-reference
Polyoxazoline multivalently conjugated with indocyanine green for sensitive in vivo photoacoustic imaging of tumors
10.1038/srep33798 · doi-reference
Radiolabelled polymeric materials for imaging and treatment of cancer: quo vadis?
10.1002/adhm.201601115 · doi-reference
Comparative efficacy of blood cell immunocamouflage by membrane grafting of methoxypoly(ethylene glycol) and polyethyloxazoline
10.1016/j.biomaterials.2013.09.016 · doi-reference
Anti-PEG antibodies associated with reduced therapeutic effect of patisiran in patients with hereditary transthyretin amyloidosis
10.1080/13506129.2024.2388713 · doi-reference
Anaphylatoxin complement 5a in Pfizer BNT162b2-induced immediate-type vaccine hypersensitivity reactions
10.3390/vaccines11061020 · doi-reference
Overcoming the PEG dilemma with poly(2-ethyl-2-oxazoline) lipids in lipid nanoparticle formulations
10.1016/j.eurpolymj.2025.114392 · doi-reference
Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson's disease – proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications
10.1016/j.eurpolymj.2016.09.052 · doi-reference
Cyclic poly(2-methyl-2-oxazoline)-lipid conjugates are good alternatives to poly(ethylene glycol)-lipids for lipid nanoparticle mRNA formulation
10.1021/acs.biomac.4c01587 · doi-reference
Tailored Monoacyl poly(2-oxazoline)- and poly(2-oxazine)-lipids as PEG-lipid alternatives for stabilization and delivery of mRNA-lipid nanoparticles
10.1021/acs.biomac.4c00651 · doi-reference
Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination
10.1016/j.vaccine.2023.05.029 · doi-reference